|
Viron's business model focuses on the identification and development of viral proteins that exhibit potent therapeutic potential. With a robust pipeline of high quality candidates, including 1 clinical, 5 preclinical and several discovery drug candidates, management is constantly balancing the need for advancement of priority programs with the need for continued development of the Company's growing and sustainable pipeline. Since its inception, Viron's business model has been focused on advancing its lead compound VT-111 through pre-clinical and early clinical development (Phase I and II). Identification of the right partner for VT-111 at the Phase II level of development will balance the needs for value creation through continued clinical advancement, with the longer term objective of demonstrating the sustainability of Viron's approach to treating a wide variety of distinct inflammatory and autoimmune diseases. Clinical stage: Viron is currently in discussions with leading pharmaceutical and biotech companies regarding a possible alliance with its lead clinical drug candidate, VT-111. Viron recently reported positive results from its Phase II trial of VT-111 in patients with Acute Coronary Syndromes (ACS) and intends to submit an IND in the near term for its second indication, the prevention of chronic organ rejection in transplant patients. Preclinical / Discovery Stage: Viron is also evaluating key strategic alliances for its discovery and preclinical drug candidates. Viron is focused on inflammatory and auto-immune based diseases. In-licensing opportunities complementary to Viron's existing developments will be evaluated based on relevant data associated with preclinical/clinical proof of principle, mechanism of action, toxicology, safety and market potential. Should you be interested in discussing partnering opportunities, both in-licensing and out-licensing arrangements, please contact:
Kevin Sullivan
By Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
By Mail:
Viron Therapeutics Inc.
By Telephone: 519.858.5120 By FAX: 519.858.5103 |
